Genomic and transcriptomic plasticity in treatment-naive ovarian cancer
about
Cancer Bioinformatic Methods to Infer Meaningful Data From Small-Size CohortsHarnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian CancerMolecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and TreatmentSpatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysisTwo different, mutually exclusively distributed, TP53 mutations in ovarian and peritoneal tumor tissues of a serous ovarian cancer patient: indicative for tumor origin?A framework for genomic biomarker actionability and its use in clinical decision makingTumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencingGenomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinomaPreferential Allele Expression Analysis Identifies Shared Germline and Somatic Driver Genes in Advanced Ovarian Cancer.Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastasesCritical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.Ovarian cancer treatment: The end of empiricism?Similarity and diversity of the tumor microenvironment in multiple metastases: critical implications for overall and progression-free survival of high-grade serous ovarian cancer.Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization.Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer.Engineering and optimising deaminase fusions for genome editing.High-grade serous ovarian cancer: the clone wars.TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2.Multiregion ultra-deep sequencing reveals early intermixing and variable levels of intratumoral heterogeneity in colorectal cancer.Involvement of DPP9 in gene fusions in serous ovarian carcinoma.Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies.Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling.Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer.Genetic Evidence for Early Peritoneal Spreading in Pelvic High-Grade Serous Cancer.Tumor evolution and chemoresistance in ovarian cancer
P2860
Q26777117-23DC527A-7FC7-4E80-93F4-9C4AB8E7C526Q26801525-8A250159-6F3E-40ED-AFCF-08DA1DAADFD7Q28066904-B02CB8D2-86F9-4546-ACCE-5A4F6E2ABEC7Q28649475-832A2EF8-5592-49D6-987C-8CFDB3CA48A8Q33865112-4419D1D2-755B-4CD3-9013-597523D55150Q34781122-5908AEF2-4D1F-4F39-AD14-BB2D9D487825Q35136473-70F3A37C-07FD-42F7-8D65-E9521DEFEE91Q35266369-125CBACB-5B27-4CC4-9E38-A3C4765B06E1Q35886692-602E79B9-E899-4D18-BCFA-C9BB1315EEEFQ36238283-1A03A282-E9EB-4AF9-A726-3002021ECABEQ36414274-5778F2B2-6659-42EE-B2EF-265AAE180D02Q36554444-71939F92-057B-49B5-AFE7-0A3D9E2D7576Q37687582-4CB00B8D-8DCF-402F-8B01-0297F14C3A3AQ38632574-DF355859-951E-4A2A-A5B3-4B8A08941FC6Q38769887-21FDB669-72D2-44E2-B286-497E1E9678AEQ38800431-95CBC759-B33A-4DE8-81D4-2827ECE79A6DQ39116957-D30322D8-3988-4D7D-86AA-515DF61A2504Q39482118-B22010B8-9E46-4E48-A54E-419F4E5F68ACQ41127895-596DCF0E-ED0C-4CAF-B40C-006B48278294Q41280464-CDE3EC86-BEC7-480A-B308-9AF25630C024Q41547803-2C54A2CF-1344-40C2-B888-3E6014BEB346Q48124146-C7F8EF01-D8DD-4A4B-BDB0-D781E8409268Q51796512-22C0A4D7-3077-471C-B44E-C2C4BC452878Q53009456-CBDD1683-FA4A-4AF0-9402-68B16EA196E4Q53100300-EB6D71A8-9CCA-4E0E-9F07-CF56C4EEE4E6Q55247640-D9160AAB-33DC-4EA0-B123-3A128386B497Q58733743-9150BAEA-C8AE-476C-9ADC-2F03646C26DA
P2860
Genomic and transcriptomic plasticity in treatment-naive ovarian cancer
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Genomic and transcriptomic plasticity in treatment-naive ovarian cancer
@en
Genomic and transcriptomic plasticity in treatment-naive ovarian cancer.
@nl
type
label
Genomic and transcriptomic plasticity in treatment-naive ovarian cancer
@en
Genomic and transcriptomic plasticity in treatment-naive ovarian cancer.
@nl
prefLabel
Genomic and transcriptomic plasticity in treatment-naive ovarian cancer
@en
Genomic and transcriptomic plasticity in treatment-naive ovarian cancer.
@nl
P2093
P2860
P356
P1433
P1476
Genomic and transcriptomic plasticity in treatment-naive ovarian cancer
@en
P2093
Clarence C Lee
Edwin Cuppen
Emile E Voest
Geert A Cirkel
Ivo Renkens
Jennifer Kreeftmeijer
Karen Duran
Marco J Koudijs
Markus J van Roosmalen
Martijn P Lolkema
P2860
P304
P356
10.1101/GR.161026.113
P577
2013-11-12T00:00:00Z